IST5-002 N6-Benzyladenosine-5'-phosphate|cas:13484-66-7|西域试剂

IST5-002 N6-Benzyladenosine-5'-phosphate,99.36%

产品编号：Bellancom-19527| CAS NO：13484-66-7| 分子式：C₁₇H₂₀N₅O₇P| 分子量：437.34

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-19527	￥3000.00	杭州北京（现货）
Bellancom-19527	￥6100.00	杭州北京（现货）
Bellancom-19527	￥9800.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

IST5-002 N6-Benzyladenosine-5'-phosphate

产品介绍

IST5-002，一种有效的 Stat5a/b 抑制剂，选择性地抑制 Stat5a/b 的转录活性，IC₅₀ 值分别为 1.5 μM (Stat5a) 和 3.5 μM (Stat5b)。 IST5-002 诱导前列腺癌细胞和慢性粒细胞白血病 (CML) 细胞凋亡 (apoptotic) 和死亡。IST5-002 可用于前列腺癌和慢性粒细胞白血病 (CML) 的研究。

生物活性

IST5-002, a potent Stat5a/b inhibitor, selectively inhibits transcriptional activity of Stat5a/b (IC₅₀s: 1.5 μM for Stat5a, 3.5 μM for Stat5b). IST5-002 inducs cell apoptotic and death of prostate cancer cells and chronic myeloid leukemia (CML) cells. IST5-002 can be used in the research of prostate cancer and chronic myeloid leukemia (CML).

体外研究

IST5-002 (1.5-25 μM, 2 h) inhibits transcriptional activity of Stat5a and Stat5b in a dose-dependent manner.
IST5-002 (0-40 μM, 3 h) inhibits Bcr-Abl-induced Stat5a/b phosphorylation in K562 cells.
IST5-002 (5-100 μM, 2 h) inhibits Stat5a/b phosphorylation in T47D cells, and inhibits dimerization in PC-3 cells.
IST5-002 (5-100 μM, 2 h) suppresses Stat5 nuclear translocation in PC-3 cells, and inhibits DNA binding of Stat5 target genes and COS-7 cells.
IST5-002 (2-50 μM, 48 h) reduces expression of Stat5a/b target genes (Bcl-xL and cyclin D1) in CWR22Rv1 and LNCaP cells.
IST5-002 (3.1-50 μM, 72 h) inhibits cell growth through induction of apoptosis in human prostate cancer cells.
IST5-002 (25-100 μM, 7 days) induces epithelial cell death in patient-derived prostate cancers ex vivo in organ explant cultures.
IST5-002 (5 μM, 24-72h) inhibits Stat5a/b phosphorylation and induces apoptosis of Imatinib (HY-15463)-sensitive and -resistant CML cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	CWR22Rv1, LNCaP, and DU145 cells
Concentration:	3.1, 6.3, 12.5, 25, 50 μM
Incubation Time:	72 h
Result:	Decreased viable cells by 50% to 80% at 12.5 μM.

Cell Cycle Analysis

Cell Line:	LNCaP and CWR22Rv1 cells
Concentration:	6, 12, 25 μM
Incubation Time:	72 h
Result:	Increased the fraction of dead cells (sub-G1) and decreased the fraction of living cells (G2–M).

Western Blot Analysis

Cell Line:	Bcr-Abl–positive K562 cells
Concentration:	0, 1, 5, 10, 20, 40 μM
Incubation Time:	3 h
Result:	Inhibited Bcr-Abl-induced Stat5a/b phosphorylation at 5 μM, without affecting Bcr-Abl tyrosine phosphorylation levels.

Immunofluorescence

Cell Line:	PC-3 cells
Concentration:	5, 10, 15. 20, 40 μM
Incubation Time:	2 h
Result:	Inhibited Prl (Prolactin)-induced nuclear translocation of Stat5.

体内研究
(In Vivo)

RORγt inverse agonist 29 (intraperitoneal injection, 25-100 mg/kg, daily for 10 days) inhibits tumor growth in prostate cancer xenograft model.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Prostate cancer (CWR22Rv1) xenograft model
Dosage:	25, 50, and 100 mg/kg
Administration:	Intraperitoneal injection, daily for 10 days
Result:	Induced massive loss of viable tumor cells and dead rounded cells accumulation. Induced cell death through apoptosis (shown by fragmented DNA in tumor sections). Decreased nuclear Stat5a/b content by 60%, 78%, and 90% at 25, 50, and 100 mg/kg, respectively.

体内研究

RORγt inverse agonist 29 (intraperitoneal injection, 25-100 mg/kg, daily for 10 days) inhibits tumor growth in prostate cancer xenograft model.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Prostate cancer (CWR22Rv1) xenograft model
Dosage:	25, 50, and 100 mg/kg
Administration:	Intraperitoneal injection, daily for 10 days
Result:	Induced massive loss of viable tumor cells and dead rounded cells accumulation. Induced cell death through apoptosis (shown by fragmented DNA in tumor sections). Decreased nuclear Stat5a/b content by 60%, 78%, and 90% at 25, 50, and 100 mg/kg, respectively.

体内研究

RORγt inverse agonist 29 (intraperitoneal injection, 25-100 mg/kg, daily for 10 days) inhibits tumor growth in prostate cancer xenograft model.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Prostate cancer (CWR22Rv1) xenograft model
Dosage:	25, 50, and 100 mg/kg
Administration:	Intraperitoneal injection, daily for 10 days
Result:	Induced massive loss of viable tumor cells and dead rounded cells accumulation. Induced cell death through apoptosis (shown by fragmented DNA in tumor sections). Decreased nuclear Stat5a/b content by 60%, 78%, and 90% at 25, 50, and 100 mg/kg, respectively.

性状

Solid

溶解性数据

In Vitro:

H₂O : 125 mg/mL (285.82 mM; Need ultrasonic)

DMSO : 125 mg/mL (285.82 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.2866 mL	11.4328 mL	22.8655 mL
5 mM	0.4573 mL	2.2866 mL	4.5731 mL
10 mM	0.2287 mL	1.1433 mL	2.2866 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式